Artivion, Inc. (AORT)
NYSE: AORT · Real-Time Price · USD
29.48
-0.17 (-0.57%)
Dec 5, 2024, 4:00 PM EST - Market closed

Company Description

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.

The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.

In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers.

It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.

The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.

Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion, Inc.
Artivion logo
Country United States
Founded 1984
IPO Date Feb 11, 1993
Industry Medical Devices
Sector Healthcare
Employees 1,500
CEO James Mackin

Contact Details

Address:
1655 Roberts Boulevard N.W.
Kennesaw, Georgia 30144
United States
Phone 770 419 3355
Website artivion.com

Stock Details

Ticker Symbol AORT
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000784199
CUSIP Number 228903100
ISIN Number US2289031005
Employer ID 59-2417093
SIC Code 3841

Key Executives

Name Position
James Patrick Mackin Chairman, President and Chief Executive Officer
Lance A. Berry CPA Executive Vice President of Finance, Chief Operating Officer and Chief Financial Officer
Amy D. Horton CPA Vice President and Chief Accounting Officer
Jean F. Holloway Esq. Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
John E. Davis Senior Vice President and Chief Commercial Officer
Matthew A. Getz Vice President of Human Resources and Chief Human Resources Officer
Dr. Marshall S. Stanton M.D. Senior Vice President of Clinical Research and Chief Medical Officer
Dr. Robert C. Thomson Vice President of Research and Development
Florian Tyrs Vice President of Global Operations

Latest SEC Filings

Date Type Title
Dec 4, 2024 144 Filing
Nov 8, 2024 10-Q Quarterly Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 8-K Current Report
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 1, 2024 144 Filing
Sep 6, 2024 UPLOAD Filing
Aug 26, 2024 144 Filing
Aug 16, 2024 144 Filing